Armagen Inc.

24 articles about Armagen Inc.

• JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc.

  4/27/2020

  JCR Pharmaceuticals Co., Ltd. announced that it has completed the previously announced acquisition of ArmaGen, Inc., a privately held US biopharmaceutical company headquartered in San Diego, California.

• ArmaGen Receives U.S. Orphan Drug Designation for AGT-184

  8/2/2018

  Novel Enzyme Replacement Therapy in Development for the Treatment of Sanfilippo A Syndrome

• ArmaGen's AGT-181 52-Week Phase 1/2 Proof-of-Concept Study Results Published in Orphanet Journal of Rare Diseases

  7/10/2018

  Novel Fusion Protein Demonstrates Neurocognitive Benefit in Children with Severe Mucopolysaccharidosis Type I (MPS I, or Hurler Syndrome), with Favorable Safety Profile

• ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children With Severe MPS I

  2/9/2018

  On a somatic level, AGT-181 stabilized urinary glycosaminoglycans, reduced liver and spleen volume including in patients previously exposed to laronidase, and further improved shoulder range of motion.

• ArmaGen's AGT-181 Granted Fast Track Designation for the Treatment of Hurler Syndrome (MPS I)

  11/30/2017

  The data suggested that AGT-181 improves neurocognitive function in patients with MPS I, demonstrating the ability of ArmaGen's proprietary drug delivery technology to transport biopharmaceuticals across the blood-brain barrier.

• ArmaGen Reports Preliminary Evidence Of Cognitive Improvement In Children With Hurler Syndrome (MPS I) Treated With AGT-181

  2/17/2017

• ArmaGen CEO: Phase II Data Shows Cognitive Improvement in Juvenile Hurler Syndrome Patients

  2/16/2017

• ArmaGen Technologies, Inc. Release: Company Appoints Mathias Schmidt, Ph.D., As Chief Executive Officer

  1/19/2017

• ArmaGen Technologies, Inc. And Rett Syndrome Research Trust Collaborate To Develop Novel Therapeutic For The Treatment Of Rett Syndrome

  7/7/2016

• ArmaGen Technologies, Inc. Announces Initiation Of Phase 2 Proof-Of-Concept Clinical Trial In Brazil To Study AGT-181 For The Treatment Of Hurler Syndrome

  3/31/2016

• ArmaGen Technologies, Inc. Receives Rare Pediatric Disease Designation From FDA For AGT-181 For The Potential Treatment Of Hurler Syndrome (Mucopolysaccharidosis Type I)

  11/5/2015

• ArmaGen Technologies, Inc. Announces First Patient Dosed In Phase 1/2a Clinical Trial Of AGT-181 For The Treatment Of Hurler Syndrome

  9/2/2015

• ArmaGen Technologies, Inc. Achieves Clinical Milestone In Hunter Syndrome Collaboration With Shire

  6/15/2015

• ArmaGen Technologies, Inc. Announces FDA Acceptance Of IND Application For AGT-181 For The Treatment Of Hurler Syndrome

  4/8/2015

• PacificGMP And ArmaGen Technologies, Inc. Announce Successful Manufacture Of Armagen's Investigational Enzyme Replacement Therapies, AGT-182 And AGT-181, For Phase 1 Clinical Trial

  3/10/2015

• ArmaGen Technologies, Inc. To Present At Oppenheimer 25th Annual Healthcare Conference

  12/5/2014

• ArmaGen Technologies, Inc. Licenses AGT-182 Rights To Shire For Up To $225M

  7/23/2014

• ArmaGen Technologies, Inc. Receives Notice Of Allowance For U.S. Patent Covering Novel Investigational Therapy For Hunter Syndrome

  6/17/2014

• ArmaGen Technologies, Inc. Expands Patent Portfolio With Issuance of Two Additional U.S. Patents

  9/4/2013

• ArmaGen Technologies, Inc. Receives US Orphan Designation for Lead Product AGT-182

  7/19/2013